Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

• Published in: The Lancet (British edition) Vol. 384; no. 9959; pp. 2046 - 2052
• Main Authors: Chang, Lee-Jah, Dowd, Kimberly A, Mendoza, Floreliz H, Saunders, Jamie G, Sitar, Sandra, Plummer, Sarah H, Yamshchikov, Galina, Sarwar, Uzma N, Hu, Zonghui, Enama, Mary E, Bailer, Robert T, Koup, Richard A, Schwartz, Richard M, Akahata, Wataru, Nabel, Gary J, Mascola, John R, Pierson, Theodore C, Graham, Barney S, Ledgerwood, Julie E
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 06.12.2014; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; Allergies; Antibodies, Neutralizing - analysis; Biological and medical sciences; Biomedical research; Chikungunya virus; Chikungunya virus - immunology; Clinical trials; Enzyme-Linked Immunosorbent Assay; Female; General aspects; Humans; Immune system; Immune Tolerance; Immunogenicity; Infectious diseases; Internal Medicine; Male; Medical sciences; Middle Aged; Safety; Vaccination; Vaccines; Vector-borne diseases; Viral infections; Viral Vaccines - administration & dosage; Viruses; USA; ISEW, Southeast Asia; ASW, Caribbean Sea; Africa; Human; Healthy subject; Virus like particle; Vaccination; Togaviridae; Vaccine; Virus; Medicine; Increasing dose; Chikungunya virus; Phase I trial; Alphavirus; Adult; Safety

Chikungunya virus—a mosquito-borne alphavirus—is endemic in Africa and south and southeast Asia and has recently emerged in the Caribbean. No drugs or vaccines are available for treatment or prevention. We aimed to assess the safety, tolerability, and immunogenicity of a new candidate vaccine. VRC 3...